Literature DB >> 15336996

Results of mitral surgery in octogenarians with isolated nonrheumatic mitral regurgitation.

Vincenzo DiGregorio1, Kenton J Zehr, Thomas A Orszulak, Charles J Mullany, Richard C Daly, Joseph A Dearani, Hartzell V Schaff.   

Abstract

BACKGROUND: Increasing numbers of elderly patients are now referred for mitral valve operations. It has been unclear whether the results offset the risk of intervention in this patient population.
METHODS: We obtained clinical follow-up through May 2002 of 59 patients 80 years or older who underwent first-time isolated mitral valve repair (46 patients) or replacement (13 patients) for nonischemic, nonrheumatic mitral regurgitation from January 1990 to June 2000. The mean duration of follow-up was 68 +/- 33 months. Observed survival was compared with the expected survival of persons of the same age and gender in the general population.
RESULTS: Preoperatively 79% of patients were in New York Heart Association (NYHA) class III-IV. Operative mortality was 1.7%. Overall 1- and 5-year survival was 89% and 61%. One- and 5-year freedom from thromboembolic complications in hospital survivors was 97% and 84%. One- and 5-year freedom from heart-related hospitalization in hospital survivors was 89% and 78%. There were no reoperations. Twenty-nine patients underwent an echocardiographic follow-up; 31% of them exhibited moderate or more regurgitation. Of 37 surviving patients at follow-up, 78% were in NYHA functional class I-II. No statistically significant difference was noted between the observed survival postoperatively and the expected survival of persons of the same age and gender in the general population. In a univariate analysis, only preoperative left ventricular ejection fraction greater than 40% was significantly associated with freedom from late heart-related mortality (95% confidence interval 62%-92%, p = 0.01) and with freedom from heart-related hospitalization (95% CI 68%-95%, p < 0.01).
CONCLUSIONS: Native mitral valve surgery for isolated nonischemic, nonrheumatic disease in octogenarians resulted in a survival rate comparable with that of the general population. It also exhibited substantial improvement regarding the functional status of the patient. Reparative techniques did not result in a survival advantage compared with replacement but did prove to be a reliable approach. Surgery performed in an early stage, preceding the development of left ventricular dysfunction, was associated with an improved freedom from late cardiac complications.

Entities:  

Mesh:

Year:  2004        PMID: 15336996     DOI: 10.1016/j.athoracsur.2004.03.041

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Heart valve surgery in octogenarians: operative and long-term results.

Authors:  Shigeaki Aoyagi; Shuji Fukunaga; Koichi Arinaga; Hiroshi Tomoeda; Koji Akasu; Tomohiro Ueda
Journal:  Heart Vessels       Date:  2010-09-29       Impact factor: 2.037

Review 2.  Cardiac surgery in the elderly patient.

Authors:  Ivar Friedrich; Andreas Simm; Joachim Kötting; Frank Thölen; Burkhard Fischer; Rolf-Edgar Silber
Journal:  Dtsch Arztebl Int       Date:  2009-06-19       Impact factor: 5.594

3.  Outcomes for mitral valve surgery among Medicare fee-for-service beneficiaries, 1999 to 2008.

Authors:  John A Dodson; Yun Wang; Mayur M Desai; Jose Augusto Barreto-Filho; Lissa Sugeng; Sabet W Hashim; Harlan M Krumholz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-05-10

4.  Mitral valve repair versus replacement in elderly patients: a systematic review and meta-analysis.

Authors:  Xiaoke Shang; Rong Lu; Mei Liu; Shuna Xiao; Nianguo Dong
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

5.  Outcome of mitral valve repair or replacement for non-ischemic mitral regurgitation: a systematic review and meta-analysis.

Authors:  Qianqian Fan; Xiaoguang Li; Guilan Cao; Puliang Yu; Fengxiao Zhang
Journal:  J Cardiothorac Surg       Date:  2021-06-15       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.